See more : Mako Mining Corp. (MKO.V) Income Statement Analysis – Financial Results
Complete financial analysis of BioVie Inc. (BIVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVie Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Visco Trade Associates Limited (VISCO.BO) Income Statement Analysis – Financial Results
- Thor Energy Plc (THR.AX) Income Statement Analysis – Financial Results
- Uniform Industrial Corporation (2482.TW) Income Statement Analysis – Financial Results
- Marvion Inc. (MVNC) Income Statement Analysis – Financial Results
- Godawari Power & Ispat Limited (GPIL.NS) Income Statement Analysis – Financial Results
BioVie Inc. (BIVI)
About BioVie Inc.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -229.38K | -266.84K | -237.42K | -229.38K | -229.38K | -229.38K | -229.38K | -229.38K | -51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.10M | 33.30M | 17.26M | 133.19M | 1.15M | 1.01M | 370.85K | 466.35K | 37.90K | 4.20K | 49.42K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.85M | 11.55M | 9.77M | 4.64M | 1.31M | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 70.06K |
| Other Expenses | 0.00 | 229.38M | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 212.71K | 247.08K | 0.00 |
| Operating Expenses | 31.95M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Cost & Expenses | 32.18M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Interest Income | 1.14M | 562.26K | 44.08K | 21.97K | 234.00 | 1.16K | 4.00 | 14.00 | 186.00 | 369.00 | 489.00 | 20.00 |
| Interest Expense | 2.89M | 4.30M | 2.16M | 559.46K | 4.77M | 273.00 | 40.96K | 0.00 | 81.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 369.00 | 489.00 | 70.06K |
| EBITDA | -31.95M | -45.69M | -23.68M | -137.80M | -2.46M | -2.27M | -2.14M | -1.32M | -380.81K | -233.01K | -321.90K | 20.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.18M | -45.08M | -27.25M | -138.05M | -2.69M | -2.50M | -2.37M | -1.55M | -432.03K | -233.38K | -322.39K | -70.06K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 59.05K | -5.18M | 1.17M | 7.80M | -13.98M | 52.29K | -40.96K | 222.94K | 105.00 | 369.00 | 489.00 | 20.00 |
| Income Before Tax | -32.12M | -50.26M | -26.08M | -130.25M | -16.68M | -2.44M | -2.41M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.30M | -3.29M | 559.46K | 4.77M | -51.40K | -1.00 | -222.93K | -105.00 | -369.00 | -489.00 | 20.00 |
| Net Income | -32.12M | -50.26M | -26.08M | -183.85M | -33.78M | -2.49M | -2.43M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.30 | -15.47 | -10.58 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| EPS Diluted | -7.30 | -15.50 | -10.60 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| Weighted Avg Shares Out | 4.52M | 3.24M | 2.46M | 1.24M | 492.00K | 253.00K | 76.00K | 71.00K | 69.00K | 69.00K | 69.00K | 32.98K |
| Weighted Avg Shares Out (Dil) | 4.52M | 3.25M | 2.47M | 1.24M | 492.95K | 253.96K | 76.61K | 71.51K | 69.76K | 69.77K | 69.67K | 32.98K |
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the...
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the...
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the...
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the...
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
CARSON CITY, Nev., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the...
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
CARSON CITY, Nev., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the...
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Genetic Technologies Limited (Nasdaq:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October...
BioVie Inc. Announces Closing of Public Offering
CARSON CITY, Nev., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the...
Crude Oil Gains Over 1%; BioVie Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging lower on Tuesday.
Source: https://incomestatements.info
Category: Stock Reports